Hillman Capital Management Inc. Lowers Position in Zimmer Biomet Holdings, Inc. $ZBH

Hillman Capital Management Inc. lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 13.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 45,969 shares of the medical equipment provider’s stock after selling 6,846 shares during the quarter. Zimmer Biomet accounts for approximately 2.6% of Hillman Capital Management Inc.’s holdings, making the stock its 17th largest position. Hillman Capital Management Inc.’s holdings in Zimmer Biomet were worth $4,134,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Gen Wealth Partners Inc purchased a new position in shares of Zimmer Biomet in the fourth quarter worth $31,000. Flagship Harbor Advisors LLC purchased a new position in shares of Zimmer Biomet in the fourth quarter worth $32,000. Grove Bank & Trust lifted its holdings in shares of Zimmer Biomet by 431.6% in the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 328 shares in the last quarter. Cornerstone Financial Management LLC purchased a new position in shares of Zimmer Biomet in the fourth quarter worth $37,000. Finally, Headlands Technologies LLC purchased a new position in shares of Zimmer Biomet in the second quarter worth $37,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the sale, the insider owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.28% of the company’s stock.

Analysts Set New Price Targets

ZBH has been the topic of several research analyst reports. Truist Financial reissued a “hold” rating and issued a $92.00 target price (down from $98.00) on shares of Zimmer Biomet in a report on Wednesday, April 29th. Leerink Partners initiated coverage on shares of Zimmer Biomet in a report on Monday, April 13th. They issued a “hold” rating and a $101.00 target price on the stock. Stifel Nicolaus lowered their target price on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating on the stock in a report on Wednesday, April 29th. Citigroup lowered their target price on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. Finally, William Blair initiated coverage on shares of Zimmer Biomet in a research note on Friday, February 20th. They set a “market perform” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $102.70.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $89.40 on Wednesday. The company has a market cap of $17.29 billion, a price-to-earnings ratio of 23.22, a PEG ratio of 2.60 and a beta of 0.47. The firm’s fifty day moving average is $87.48 and its 200 day moving average is $90.29. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. The company had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. Zimmer Biomet’s revenue was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.49 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio is presently 24.94%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.